In mice with a specific genetic modification affecting gut cells, consuming phytic acid at a dose of 2% of body weight restores HDAC3 enzyme function, decreases a specific epigenetic mark on genes...

We analyzed the available evidence and found that in mice with a genetic deletion affecting intestinal cells, oral phytic acid at a dose of 2% of body weight was associated with restored HDAC3 enzyme activity, reduced levels of a specific epigenetic mark linked to matrix metalloproteinase genes, lower production of those enzymes, and improved intestinal barrier integrity [1]. This single assertion is supported by 12.0 studies or observations, with no studies contradicting it. The evidence we’ve reviewed so far leans toward the idea that phytic acid, when consumed orally, may help reverse some of the changes caused by IPMK deletion in gut cells. HDAC3 is an enzyme involved in regulating gene activity through epigenetic mechanisms, and its reduced function in these mice appears to be linked to increased breakdown of the intestinal lining. Phytic acid, a naturally occurring compound in plant foods like grains and legumes, seems to counteract this by influencing gene expression patterns and reducing the activity of enzymes that can damage the barrier. However, this finding comes from one set of experiments in genetically modified mice, and we have no data on whether this effect occurs in humans, at different doses, or with other forms of phytic acid. We also don’t know how long the effects last or whether they translate to measurable health outcomes like reduced inflammation or improved digestion. What we’ve found so far is limited to a specific mouse model and a single dosage. More research would be needed to understand if this mechanism applies beyond these conditions. For now, the data suggest phytic acid might play a role in supporting gut barrier function in this particular biological context — but it’s too early to say whether this would matter for human health.